Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
作者信息
Parks Anna L, McWhirter Ryan M, Evason Kimberley, Kelley Robin K
机构信息
School of Medicine, University of California, San Francisco (UCSF), 505 Parnassus Ave., San Francisco, CA, 94143, USA.
出版信息
J Gastrointest Cancer. 2015 Jun;46(2):161-5. doi: 10.1007/s12029-015-9690-7.
Abstract
摘要
相似文献
1
Cases of spontaneous tumor regression in hepatobiliary cancers: implications for immunotherapy?
J Gastrointest Cancer. 2015 Jun;46(2):161-5. doi: 10.1007/s12029-015-9690-7.
2
Immunometabolism: A novel perspective of liver cancer microenvironment and its influence on tumor progression.
World J Gastroenterol. 2018 Aug 21;24(31):3500-3512. doi: 10.3748/wjg.v24.i31.3500.
3
Treating Hepatobiliary Cancer: The Immunologic Approach.
Dig Dis. 2017;35(4):390-396. doi: 10.1159/000456593. Epub 2017 May 3.
4
Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy.
Clin Cancer Res. 2022 Feb 1;28(3):540-551. doi: 10.1158/1078-0432.CCR-21-1219. Epub 2021 Nov 16.
5
Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma.
J Clin Gastroenterol. 2011 Jan;45(1):69-75. doi: 10.1097/MCG.0b013e3181ce5dfa.
6
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27.
7
Systemic Therapy for Primary Liver Tumors: Cholangiocarcinoma and Hepatocellular Carcinoma.
Surg Oncol Clin N Am. 2019 Oct;28(4):695-715. doi: 10.1016/j.soc.2019.06.015.
8
Combined hepatocellular carcinoma and cholangiocarcinoma: a case report and review of the literature.
Hepatobiliary Pancreat Dis Int. 2007 Dec;6(6):656-9.
9
[A case of successful multimodal treatment for combined hepatocellular and cholangiocarcinoma with portal venous tumor thrombus].
Gan To Kagaku Ryoho. 2009 Nov;36(12):2374-6.
10
Lymphoepithelioma-Like Carcinoma in Liver.
Am J Pathol. 2017 Jul;187(7):1438-1444. doi: 10.1016/j.ajpath.2017.02.022. Epub 2017 May 10.
引用本文的文献
1
Complete regression of intrahepatic cholangiocarcinoma after right portal vein ligation. Case report.
Int J Surg Case Rep. 2024 Apr;117:109580. doi: 10.1016/j.ijscr.2024.109580. Epub 2024 Mar 24.
2
Rapid Dissemination followed by Spontaneous Regression of Metastatic Hepatocellular Carcinoma after Liver Radiofrequency Thermal Ablation: A Case Report with Correlative Immune Assay.
Case Rep Oncol. 2023 Mar 1;16(1):129-136. doi: 10.1159/000527229. eCollection 2023 Jan-Dec.
3
Efficacy and security of tumor vaccines for hepatocellular carcinoma: a systemic review and meta-analysis of the last 2 decades.
J Cancer Res Clin Oncol. 2023 Apr;149(4):1425-1441. doi: 10.1007/s00432-022-04008-y. Epub 2022 Apr 28.
4
Therapeutic Vaccines against Hepatocellular Carcinoma in the Immune Checkpoint Inhibitor Era: Time for Neoantigens?
Int J Mol Sci. 2022 Feb 11;23(4):2022. doi: 10.3390/ijms23042022.
5
Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer.
Onco Targets Ther. 2021 Mar 12;14:1873-1882. doi: 10.2147/OTT.S269671. eCollection 2021.
6
Abscopal Resolution of a Hepatic Metastasis in a Patient with Metastatic Cholangiocarcinoma Following Radical Stereotactic Body Radiotherapy to a Synchronous Early Stage Non-small Cell Lung Cancer.
Cureus. 2019 Feb 16;11(2):e4082. doi: 10.7759/cureus.4082.
7
Spontaneous regression of hepatocellular carcinoma: A mini-review.
World J Gastroenterol. 2017 Jun 7;23(21):3797-3804. doi: 10.3748/wjg.v23.i21.3797.
8
The Promise of Immunotherapy in the Treatment of Hepatocellular Carcinoma.
Am Soc Clin Oncol Educ Book. 2017;37:311-317. doi: 10.1200/EDBK_175230.
9
Specific immunotherapy in hepatocellular cancer: A systematic review.
J Gastroenterol Hepatol. 2017 Feb;32(2):339-351. doi: 10.1111/jgh.13449.
本文引用的文献
1
A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C.
J Hepatol. 2013 Jul;59(1):81-8. doi: 10.1016/j.jhep.2013.02.022. Epub 2013 Mar 4.
2
Melanoma as a model tumour for immuno-oncology.
Ann Oncol. 2012 Sep;23 Suppl 8:viii10-4. doi: 10.1093/annonc/mds257.
3
Regression of a renal cell carcinoma following allogeneic peripheral blood stem cell transplant for acute myeloid leukaemia: evidence of a graft-versus-tumour effect without significant graft-versus-host disease.
Br J Haematol. 2012 Oct;159(1):1. doi: 10.1111/j.1365-2141.2012.09238.x. Epub 2012 Jul 27.
4
Immunologic correlates of the abscopal effect in a patient with melanoma.
N Engl J Med. 2012 Mar 8;366(10):925-31. doi: 10.1056/NEJMoa1112824.
5
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
Int J Cancer. 2010 Dec 15;127(12):2893-917. doi: 10.1002/ijc.25516.
6
Potential of immunotherapy for hepatocellular carcinoma.
J Hepatol. 2011 Apr;54(4):830-4. doi: 10.1016/j.jhep.2010.10.013. Epub 2010 Nov 9.
7
Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.
Clin Cancer Res. 2009 Dec 1;15(23):7412-20. doi: 10.1158/1078-0432.CCR-09-1624. Epub 2009 Nov 24.
8
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial.
Lancet Oncol. 2009 Jan;10(1):25-34. doi: 10.1016/S1470-2045(08)70285-7. Epub 2008 Dec 16.
9
Spontaneous regression of hepatocellular carcinoma: three case reports and a categorized review of the literature.
Dig Dis Sci. 2009 May;54(5):1147-53. doi: 10.1007/s10620-008-0447-z. Epub 2008 Aug 21.
10
Sorafenib in advanced hepatocellular carcinoma.
N Engl J Med. 2008 Jul 24;359(4):378-90. doi: 10.1056/NEJMoa0708857.
Zotero 插件